Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 2, pp 303–305 | Cite as

ILP and RT: The Study That Will Never Be

Bone and Soft Tissue Sarcomas

Notes

Conflicts of interest

The authors declare no conflict of interest.

References

  1. 1.
    Deroose JP, Burger JWA, van Geel AN, et al. Radiotherapy for soft tissue sarcoma after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol. 2010. doi:  10.1245/s10434-010-1400-x.
  2. 2.
    Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756–64.Google Scholar
  3. 3.
    Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFa and melphalan for non-resectable soft tissue sarcomas of the extremities. Eur J Surg Oncol. 2000;26:669–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol. 2009;16:3350–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Hayes AJ, Neuhaus SJ, Clark MA, et al. Isolated limb perfusion with Melphalan and tumor necrosis factor alpha for advanced melanoma and soft tissue sarcoma. Ann Surg Oncol. 2007;14:230–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol. 2007;14:553–9.PubMedCrossRefGoogle Scholar
  7. 7.
    van Ginkel RJ, Thijssens KM, Pras E, et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol. 2007;14:1499–506.PubMedCrossRefGoogle Scholar
  8. 8.
    Hohenberger P, et al. Functional outcome after preoperative isolated limb perfusion with rhTNFalpha/melphalan for high-grade extremity sarcoma. Eur J Cancer. 2001;37:S34–5.CrossRefGoogle Scholar
  9. 9.
    Grabellus F, Kraft C, Sheu SY, et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol. 2009;16:676–86.PubMedCrossRefGoogle Scholar
  10. 10.
    Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003;98:1483–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Gronchi A, Palmerini E, Demetri G, et al. 2009. A phase II clinical trial of neoadjuvant trabectedin in patients with non metastatic advanced myxoid/round cell liposarcoma (MRCL). Eur J Cancer. 7: 589.Google Scholar
  12. 12.
    Thijssens KM, van Ginkel RJ, Pras E, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann Surg Oncol. 2006;13:518–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Muret J, Yacoub M, Terrier P, et al. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol. 2008;19:793–800.PubMedCrossRefGoogle Scholar
  14. 14.
    Hoven-Gondrie ML, Thijssens KM, Van den Dungen JJ, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2007;14:2105–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246:675–81.PubMedCrossRefGoogle Scholar
  16. 16.
    Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251:506–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Bonvalot S, Dunant A, le Pechoux C, et al. Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS). J Clin Oncol. 2010;28(15_suppl):10068.Google Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  1. 1.Department of SurgeryInstitut Gustave RoussyVillejuifFrance
  2. 2.Department of SurgeryIstituto Nazionale TumoriMilanItaly

Personalised recommendations